Prospective evaluation of Carcinoembryonic Antigen (CEA) and carbohydrate antigen 15.3 (CA 15.3) in patients with primary locoregional breast cancer

Clinical Chemistry

Volumn 56, Issue 7, 2010, Pages 1148-1157

  Molina, Rafael ^a   Auge, Jose M ^a   Farrus, Blanca ^a   Zanón, Gabriel ^a   Pahisa, Jaume ^a   Muñoz, Montserrat ^a   Torne, Aureli ^a   Filella, Xavier ^a   Escudero, Jose M ^a   Fernandez, Pedro ^a   Velasco, Martin ^a  

^a HOSPITAL CLÍNIC   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOHYDRATE ANTIGEN; CARBOHYDRATE ANTIGEN 15.3; CARCINOEMBRYONIC ANTIGEN; ESTROGEN RECEPTOR; TUMOR MARKER; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CANCER STAGING; DISEASE FREE SURVIVAL; FEMALE; GLEASON SCORE; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; RECURRENT DISEASE; TUMOR VOLUME;

ANALYSIS OF VARIANCE; BREAST NEOPLASMS; BREAST NEOPLASMS, MALE; CARCINOEMBRYONIC ANTIGEN; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; FEMALE; HUMANS; LYMPHATIC METASTASIS; MALE; MUCIN-1; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE;

EID: 77954355661     PISSN: 00099147     EISSN: 15308561     Source Type: Journal    
DOI: 10.1373/clinchem.2009.135566     Document Type: Article

References (37)

1. Molina R, Barak V, van Dalen A, Duffy MJ, Einarsson R, Gion M, et al. Tumor markers in breast cancer. European Group on Tumor Markers Recommendations. Tumour Biol 2005;26:281-93.
2. Sturgeon CM, Duffy MJ, Stenman UH, Lilja H, Brünner N, Chan DW, et al. National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers. Clin Chem 2008;54:e11-79.
3. Molina R, Zanon G, Filella X, Moreno F, Jo J, Daniels M, et al. Use of serial carcinoembryonic antigen and CA 15.3 assays in detecting relapses in breast cancer patients. Breast Cancer Res Treat 1995;36:41-8.
4. Cheung KL, Graves CR, Robertson JF. Tumour marker measurements in the diagnosis and monitoring of breast cancer. Cancer Treat Rev 2000;26:91-102. (Pubitemid 30182241)
5. Duffy MJ. Serum tumor markers in breast cancer: are they of clinical value? Clin Chem 2006;52:345-51.
6. Harris L, Fritsche H, Mennel R, Norton L, Ravdin P, Taube S, et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 2007;25:5287-312.
7. Hayes DF, Bast RC, Desch CE, Fritsche H Jr, Kemeny NE, Jessup JM, et al. Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers. J Natl Cancer Inst 1996;88:1456-66.
8. Stieber P, Molina R, Chan DW, Fritsche, Beyrau R, Bonfrer JM, et al. Clinical evaluation of the Elecsys CA 15.3 test in breast cancer patients. Clin Lab 2003;49:15-24. (Pubitemid 36221756)
9. O'Hanlon DM, Kerin MJ, Koent P, Maher D, Grimes H, Given HF. An evaluation of preoperative CA15.3 measurement in primary breast carcinoma. Br J Cancer 1995;71:1288-91.
10. Martinez-Trufero J, de Lobera AR, Lao J, Puértolas T, Artal-Cortés A, Zorrilla M, et al. Serum markers and prognosis in locally advanced breast cancer. Tumori 2005;91:522-30.
11. Fehm T, Maimonis P, Weitz S, Teramoto Y, Katalinic A, Jager W. Influence of circulating c-erbB-2 serum protein on response to adjuvant chemotherapy in node-positive breast cancer patients. Breast Cancer Res Treat 1997;43:87-95. (Pubitemid 27090870)
12. Gion M, Mione R, Nascimben O, Valsecchi M, Gatti C, Leon A, Bruscagnin G. The tumour associated antigen CA15.3 in primary breast cancer: evaluation of 667 cases. Br J Cancer 1991;63:809-13.
13. McLauglin R, McGrath J, Grimes H, Given HF. The prognostic value of the tumor marker CA 15.3 at initial diagnosis of patients with breast cancer. Int J Biol Markers 2000;15:340-2. (Pubitemid 32041149)
14. Ebeling FC, Schmitt UM, Untch M, Nagel D, Fateh-Moghadam A, Stieber P, Seidel D. Tumour markers CEA and CA 15.3 as prognostic factors in breast cancer: univariate and multivariate analysis. Anticancer Res 1999;19:2545-50. (Pubitemid 29392410)
15. Gion M, Boracchi P, Dittadi R, Biganzoli E, Peloso L, Mione R, et al. Prognostic role of serum CA15.3 in 362 node-negative breast cancers. An old player for a new game. Eur J Cancer 2002;38:1181-8. (Pubitemid 34603477)
16. Molina R, Jo J, Filella X, Zanon G, Pahisa J, Muñoz M, et al. C-erbB-2 oncoprotein, CEA, and CA 15.3 in patients with breast cancer: prognostic value. Breast Cancer Res Treat 1998;51:109-19.
17. Ebeling FG, Stieber P, Untch M, Nagel D, Konecny GE, Schmitt UM, et al. Serum CEA and CA 15-3 as prognostic factors in primary breast cancer. Br J Cancer 2002;86:1217-22.
18. Molina R, Jo J, Filella X, Zanon G, Pahisa J, Muñoz M, et al. C-erbB-2 oncoprotein in the sera and tissue of patients with breast cancer: utility in prognosis. Anticancer Res 1996;16:2295-300. (Pubitemid 26265581)
19. Duffy MJ, Duggan C, Keane R, Hill AD, McDermott E, Crown J, O'Higgins N. High preoperative CA 15-3 concentrations predict adverse outcome in node-negative and node-positive breast cancer: study of 600 patients with histologically confirmed breast cancer. Clin Chem 2004;50:559-63. (Pubitemid 38297306)
20. Heinze T, Schurenkamper P, Minguillon C, Lichtenegger W. Mammary serum antigen (MSA), Ca 549, CA 15-3 and CEA in breast cancer preoperative sensitivity and correlation to prognostic factors. Anticancer Res 1997;17:2953-4.
21. Guadagni F, Ferroni P, Carlini S, Mariotti S, Spila A, Aloe S, et al. A re-evaluation of carcinoembryonic antigen (CEA) as a serum marker for breast cancer: a prospective longitudinal study. Clin Cancer Res 2001;7:2357-62.
22. Canizares F, Sola J, Perez M, Tovar I, De Las Heras M, Salinas J, et al. Preoperative values of CA 15-3 and CEA as prognostic factors in breast cancer: a multivariate analysis. Tumour Biol 2001;22:273-81.
23. Lumachi F, Ermani M, Brandes AA, Basso S, Basso U, Boccagni P. Predictive value of different prognostic factors in breast cancer recurrences: multivariate analysis using a logistic regression model. Anticancer Res 2001;21:4105-8.
24. Park BW, Oh JW, Kim JH, Park SH, Kim KS, Kim JH, Lee KS. Preoperative CA 15.3 and CEA serum levels for breast cancer outcome. Ann Oncol 2008;19:675-81.
25. Uehara M, Kinoshita T, Hojo T, Akashi-Tanaka S, Iwamoto E, Fukutomi T. Long-term prognostic study of carcinoembryonic antigen (CEA) and carbohydrate antigen 15-3 (CA 15-3) in breast cancer. Int J Clin Oncol 2008;13:447-51.
26. Molina R, Filella X, Zanon G, Pahisa J, Alicarte J, Munoz M, et al. (2003). Prospective evaluation of tumor markers (c-erbB-2 oncoprotein, CEA and CA 15.3) in patients with loco-regional breast cancer. Anticancer Res 2003;23:1043-50.
27. Molina R, Filella X, Alicarte J, Zanon G, Pahisa J, Munoz M, et al. Prospective evaluation of CEA and CA 15.3 in patients with locoregional breast cancer. Anticancer Res 2003;23:1035-41.
28. Piccart MJ, Di Leo A, Hamilton A. HER2: a predictive factor ready to use in the daily management of breast cancer patients? Eur J Cancer 2000;36:1755-61.
29. Harbeck N, Kates RE, Look MP, Meijer-Van Gelder ME, Klijn JG, Krüger A, et al. Enhanced benefit from adjuvant chemotherapy in breast cancer patients classified high-risk according to urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (n = 3424). Cancer Res 2002;62:4617-22.
30. Soussi T, Beroud C. Assessing TP53 status in human tumours to evaluate clinical outcome. Nat Rev Cancer 2001;1:233-40.
31. Look MP, van Putten WL, Duffy MJ, Harbeck N, Christensen IJ, Thomssen C, et al. Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients. J Natl Cancer Inst 2002;94:116-28.
32. Foekens JA, Look MP, Bolt-de Vries J, Meijer-Van Gelder ME, van Putten WL, Klijn JG. Cathepsin-D in primary breast cancer: prognostic evaluation involving 2810 patients. Br J Cancer 1999;79:300-7.
33. Molina R, Auge JM, Escudero JM, Marrades R, Viñolas N, Carcereny E, et al. Mucins CA 125, CA 199, CA 15.3, and TAG 72.3 as tumor markers in patients with lung cancer: comparison with CYFRA 21-1, CEA, SCC and NSE. Tumour Biol 2008;29:371-80.
34. Molina R, Augé JM, Bosch X, Escudero JM, Viñolas N, Marrades R, et al. Usefulness of serum tumor markers, including progastrin-releasing peptide in patients with lung cancer: correlation with histology. Tumour Biol 2009;30:121-9.
35. Giovanella L, Ceriani L, Giardina G, Bardelli D, Tanzi F, Garancini S. Serum cytokeratin fragment 21.1 (CYFRA 21.1) as tumour marker for breast cancer: comparison with carbohydrate antigen 15.3 (CA 15.3) and carcinoembryonic antigen (CEA). Clin Chem Lab Med 2002;40:298-303.
36. Kumpulainen EJ, Keskikuru RJ, Johansson RT. Serum tumor marker CA 15.3 and stage are the two most powerful predictors of survival in primary breast cancer. Breast Cancer Res Treat 2002;76:95-102.
37. Balch ChM, Buzaid AC, Soong SJ, Thompson JF, Atkins MB, Byrd DR, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009;27:6199-206.